Evaluation of Artesunate in Infants Being Treated for Severe Malaria

Last updated: December 5, 2024
Sponsor: Amivas (US), LLC
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Artesunate Injection

Clinical Study ID

NCT06555809
IVAS-PEDS-PK-1
  • Ages 1-23
  • All Genders

Study Summary

This is essentially a laboratory study that is an addendum to an ongoing prospective Phase 4 multicenter observational study titled: "Safety and Efficacy of Artesunate in Pregnant Women and Infants (ARTEMUM)" being conducted in France. Infants, the parents of whom provided consent to have data collected from their child as part of the ARTEMUM study, will have an additional blood sample collected when other standard of care blood specimens are collected during the 2-day period after the start of intravenous (IV) artesunate treatment. A maximum of 4 samples will be taken and plasma will be isolated and stored frozen until analysis for plasma artesunate and dihydroartemisinin (DHA) concentrations. Red blood cells will also be frozen for further analysis (for example Kelch-13 mutations). In addition, a standard of care blood sample will be collected approximately one month post treatment for clinical laboratory tests.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Parental consent provided to the ARTEMUM Study

  • Parental consent provided to participate in this PK Laboratory Study

  • Infants < 2 years of age with malaria (positive blood by polymerase chain reaction (PCR) or thin or thick smear or rapid diagnostic test (RDT), or any combination ofthose) treated by at least 1 dose of intravenous artesunate

Exclusion

Exclusion Criteria:

  • Hemoglobin < 7.0 g/dL at the time when additional blood sample for PK assessmentwill be drawn as part of standard of care

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: Artesunate Injection
Phase:
Study Start date:
October 06, 2024
Estimated Completion Date:
February 28, 2030

Study Description

This is essentially a laboratory study that is an addendum to an ongoing prospective Phase 4 multicenter observational study titled: "Safety and Efficacy of Artesunate in Pregnant Women and Infants (ARTEMUM)" being conducted in France. Parents of infants under 2 years of age who provided consent to participate in the ARTEMUM study will be asked to provide consent for their child to this laboratory study providing the infant was eligible for the ARTEMUM study. During the first 48 hours after the start of IV artesunate treatment, a maximum of 4 samples of blood will be collected when other standard of care samples are being collected. With regard to blood collected for standard of care, it is recognized that samples between 0.25 and 5 hours post doses will be the most useful for pharmacokinetic (PK) analysis due to the 30-to-45-minute half-life of DHA. Plasma will be isolated and frozen until submission to the central laboratory for artesunate and DHA plasma concentrations. In addition, a standard of care blood sample will be collected approximately one month post treatment for clinical laboratory tests. The recommendation by the World Health Organization (WHO) is followed in France not only for safety (anemia) but also for relapse. Clinical laboratory test results and other data to be included in the analysis will be abstracted from the case report forms (CRFs) from the ARTEMUM study.

Connect with a study center

  • Hôpital Cochin Port Royal

    Paris, 75014
    France

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.